Mia Hashibe1,2, Sarah Abdelaziz3,4, Mohammed Al-Temimi3, Alison Fraser5, Kenneth M Boucher4,6, Ken Smith5, Yuan-Chin Amy Lee3, Kerry Rowe7, Braden Rowley7, Micky Daurelle8, Avery E Holton9, James VanDerslice3, Lorenzo Richiardi10, Jay Bishoff11, Will Lowrance4,12, Antoinette Stroup6. 1. Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, 375 Chipeta Way, Suite A, Salt Lake City, UT, USA. mia.hashibe@utah.edu. 2. Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, 84108, USA. mia.hashibe@utah.edu. 3. Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, 375 Chipeta Way, Suite A, Salt Lake City, UT, USA. 4. Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, 84108, USA. 5. Pedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA. 6. Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. 7. Medical Informatics, Intermountain Healthcare, Salt Lake City, UT, USA. 8. University of Utah Health Sciences Center, Salt Lake City, UT, USA. 9. Department of Communication, University of Utah, Salt Lake City, UT, USA. 10. Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin, Turin, Italy. 11. Intermountain Urological Institute, Salt Lake City, UT, USA. 12. Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
Abstract
PURPOSE: Testicular cancer is diagnosed at a young age and survival rates are high; thus, the long-term effects of cancer treatment need to be assessed. Our objectives are to estimate the incidence rates and determinants of late effects in testicular cancer survivors. METHODS: We conducted a population-based cohort study of testicular cancer survivors, diagnosed 1991-2007, followed up for a median of 10 years. We identified 785 testicular cancer patients who survived ≥5 years and 3323 men free of cancer for the comparison group. Multivariate Cox regression analysis was used to compare the hazard ratio between the cases and the comparison group and for internal analysis among case patients. RESULTS: Testicular cancer survivors experienced a 24 % increase in risk of long-term health effects >5 years after diagnosis. The overall incidence rate of late effects among testicular cancer survivors was 66.3 per 1000 person years. Higher risks were observed among testicular cancer survivors for hypercholesterolemia, infertility, and orchitis. Chemotherapy and retroperitoneal lymph node dissection appeared to increase the risk of late effects. Being obese prior to cancer diagnosis appeared to be the strongest factor associated with late effects. CONCLUSIONS: Testicular cancer survivors were more likely to develop chronic health conditions when compared to cancer-free men. IMPLICATIONS FOR CANCER SURVIVORS: While the late effects risk was increased among testicular cancer survivors, the incidence rates of late effects after cancer diagnosis was fairly low.
PURPOSE:Testicular cancer is diagnosed at a young age and survival rates are high; thus, the long-term effects of cancer treatment need to be assessed. Our objectives are to estimate the incidence rates and determinants of late effects in testicular cancer survivors. METHODS: We conducted a population-based cohort study of testicular cancer survivors, diagnosed 1991-2007, followed up for a median of 10 years. We identified 785 testicular cancerpatients who survived ≥5 years and 3323 men free of cancer for the comparison group. Multivariate Cox regression analysis was used to compare the hazard ratio between the cases and the comparison group and for internal analysis among case patients. RESULTS:Testicular cancer survivors experienced a 24 % increase in risk of long-term health effects >5 years after diagnosis. The overall incidence rate of late effects among testicular cancer survivors was 66.3 per 1000 person years. Higher risks were observed among testicular cancer survivors for hypercholesterolemia, infertility, and orchitis. Chemotherapy and retroperitoneal lymph node dissection appeared to increase the risk of late effects. Being obese prior to cancer diagnosis appeared to be the strongest factor associated with late effects. CONCLUSIONS:Testicular cancer survivors were more likely to develop chronic health conditions when compared to cancer-free men. IMPLICATIONS FOR CANCER SURVIVORS: While the late effects risk was increased among testicular cancer survivors, the incidence rates of late effects after cancer diagnosis was fairly low.
Entities:
Keywords:
Cardiovascular disease; Late effects; Obesity; Testicular cancer
Authors: H S Haugnes; N Aass; S D Fosså; O Dahl; O Klepp; E A Wist; J Svartberg; T Wilsgaard; R M Bremnes Journal: Ann Oncol Date: 2006-10-23 Impact factor: 32.976
Authors: J A Gietema; D T Sleijfer; P H Willemse; H Schraffordt Koops; E van Ittersum; W M Verschuren; D Kromhout; W J Sluiter; N H Mulder; E G de Vries Journal: Ann Intern Med Date: 1992-05-01 Impact factor: 25.391
Authors: Alexandra W van den Belt-Dusebout; Janine Nuver; Ronald de Wit; Jourik A Gietema; Wim W ten Bokkel Huinink; Patrick T R Rodrigus; Erik C Schimmel; Berthe M P Aleman; Flora E van Leeuwen Journal: J Clin Oncol Date: 2006-01-20 Impact factor: 44.544
Authors: Hege S Haugnes; George J Bosl; Hink Boer; Jourik A Gietema; Marianne Brydøy; Jan Oldenburg; Alv A Dahl; Roy M Bremnes; Sophie D Fosså Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Philip Blach Rossen; Anette Fischer Pedersen; Robert Zachariae; Hans von der Maase Journal: J Clin Oncol Date: 2009-10-26 Impact factor: 44.544
Authors: Clair J Beard; Lois B Travis; Ming-Hui Chen; Nils D Arvold; Paul L Nguyen; Neil E Martin; Deborah A Kuban; Andrea K Ng; Karen E Hoffman Journal: Cancer Date: 2013-04-30 Impact factor: 6.860
Authors: Marianne Brydøy; Jan Oldenburg; Olbjørn Klepp; Roy M Bremnes; Erik A Wist; Tore Wentzel-Larsen; Erik R Hauge; Olav Dahl; Sophie D Fosså Journal: J Natl Cancer Inst Date: 2009-12-16 Impact factor: 13.506
Authors: Pavlos Msaouel; Mehmet A Bilen; Miao Zhang; Matthew Campbell; Jennifer Wang; Shi-Ming Tu Journal: Curr Opin Oncol Date: 2017-05 Impact factor: 3.645
Authors: Peter J Siska; Romany A N Johnpulle; Alice Zhou; Jennifer Bordeaux; Ju Young Kim; Bashar Dabbas; Naveen Dakappagari; Jeffrey C Rathmell; W Kimryn Rathmell; Alicia K Morgans; Justin M Balko; Douglas B Johnson Journal: Oncoimmunology Date: 2017-03-20 Impact factor: 8.110
Authors: Andreas G Wibmer; Paul C Dinh; Lois B Travis; Carol Chen; Maria Bromberg; Junting Zheng; Marinela Capanu; Howard D Sesso; Darren R Feldman; Hebert Alberto Vargas Journal: JNCI Cancer Spectr Date: 2022-07-01
Authors: Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis Journal: J Clin Oncol Date: 2018-04-04 Impact factor: 44.544
Authors: Anne H Blaes; Daniel A Mulrooney; Rachel Isaksson Vogel; Anna Solovey; Robert Hebbel; Bruce A Peterson; Joseph P Neglia; Carter Biewen; Suma H Konety; Daniel A Duprez Journal: Vasc Health Risk Manag Date: 2018-09-10
Authors: Giuseppe Schepisi; Silvia De Padova; Delia De Lisi; Chiara Casadei; Elena Meggiolaro; Federica Ruffilli; Giovanni Rosti; Cristian Lolli; Giorgia Ravaglia; Vincenza Conteduca; Alberto Farolfi; Luigi Grassi; Ugo De Giorgi Journal: Front Endocrinol (Lausanne) Date: 2019-02-25 Impact factor: 5.555
Authors: Vaibhav Agrawal; Paul C Dinh; Chunkit Fung; Patrick O Monahan; Sandra K Althouse; Kelli Norton; Clint Cary; Lawrence Einhorn; Sophie D Fossa; Nabil Adra; Lois B Travis Journal: JNCI Cancer Spectr Date: 2019-10-08